Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 1,601–1,700 of 3,636
What is the Optimal Low-Density Lipoprotein Cholesterol?
Gagel, A., Zghyer, F., Samuel, C., & Martin, S. S. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.005 · Cited by 10
Aggressive lipid-lowering therapy after percutaneous coronary intervention – for whom and how?
Lee, Z.-V., & Lam, H. (2022) · AsiaIntervention · doi:10.4244/aij-d-22-00005 · Cited by 10
Considerations for routinely testing for high lipoprotein(a)
Nurmohamed, N. S., Moriarty, P. M., & Stroes, E. S. G. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000838 · Cited by 11
“ODYSSEY Outcomes trials, respectively [21,22].”
BackgroundMackinnon, E. S., Har, B., Champsi, S., Wani, R. J., Geyer, L., Shaw, E., Farris, M. S., & Anderson, T. J. (2023) · Cardiology and Therapy · doi:10.1007/s40119-022-00300-7 · Cited by 7
“2017/18, [9, 27] and while uptake has steadily increased with improved access since that time, Cardiol Ther (2023) 12:327–338 335”
BackgroundReal-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use
Kim, O. M., Givens, T. K., Tang, E. G., Schimmer, J. J., Ramsey, T., Boyd, K., & Delate, T. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001404 · Cited by 9
Cobo, A. L., Masson, W. M., Lobo, M., Barbagelata, L., Forte, E. H., Corral, P., & Nogueira, J. P. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101940 · Cited by 8
In-hospital initiation of PCSK9 inhibitors in ACS: pros and cons
Krychtiuk, K. A., Claeys, M. J., Gencer, B., et al. (2023) · EuroIntervention · doi:10.4244/eij-e-23-00014 · Cited by 8
Nagendra, L., Mahajan, K., Gupta, G., & Dutta, D. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.09.005 · Cited by 8
“16,17 There is accumulating evidence for early LDL lowering and improved cardiovascular outcomes with the use of PCSK9i in the early phase of an ACS event.”
BackgroundEscobar, C., Barrios, V., Cequier, A. R., Cosín-Sales, J., Seijas‐Amigo, J., Gómez‐Doblas, J. J., Arrarte, V., Tuñón, J., & Banach, M. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.10.002 · Cited by 7
Alshahrani, A. S., Kholaif, N., Al-Khnifsawi, M., ZARIF, H. A., & Mahzari, M. M. (2024) · Advances in Therapy · doi:10.1007/s12325-023-02764-y · Cited by 11
“Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) promote hepatic uptake of LDL-C by LDLR [13, 14], and clinical trials have shown their efficacy in reducing LDL-C levels and improving cardiovascular outcomes [15, 16].”
Xu, Q., Li, C., Jing, P., Li, H., Tian, X., Xia, X., Zhang, Y., Zhang, X., Wang, Y., Wang, A., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64704 · Cited by 8
Kayani, T., Ahmad, B., Chang, R., Qian, F., Sahinoz, M., Rehan, M., Giaimo, A., Spatz, E. S., & Hu, J. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3010009 · Cited by 16
Noseda, R., Bedussi, F., Panchaud, A., & Ceschi, A. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3269 · Cited by 8
Velidakis, N., Stachteas, P., Gkougkoudi, E., Papadopoulos, C. E., & Kadoglou, N. P. E. (2024) · Pharmaceuticals · doi:10.3390/ph17050568 · Cited by 9
“The most common side effects include mild injection-site reactions [69].”
BackgroundManagement of dyslipidaemias in the elderly population—A narrative review
Anagnostis, P. G., Vaitsi, K., Veneti, S., Georgiou, T., Paschou, S. Α., Lambrinoudaki, I. V., & Goulis, D. G. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.03.011 · Cited by 10
Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?
Qamar, A., & Libby, P. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1160-6 · Cited by 8
Rana, K., Reid, J., Rosenwasser, J. N., Lewis, T., Sheikh‐Ali, M., Choksi, R. R., & Goldfaden, R. F. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s167375 · Cited by 8
“trial and only 49 patients would need to be treated for 4 years to prevent the occurrence of one primary end-point event.(43) A subgroup analysis of ODYSSEY OUTCOMES was completed on patients with diabetes.”
BackgroundRegression analysis of recurrent‐event‐free time from multiple follow‐up windows
Xia, M., Murray, S., & Tayob, N. (2019) · Statistics in Medicine · doi:10.1002/sim.8385 · Cited by 9
“Two features of our data need to be addressed for successful estimation of model (3): (1) the censored nature of the vector of newly formatted longitudinal outcomes, i, from patient i, and (2) the correlated nature of these longitudinal outcomes.”
BackgroundMethodInfluentialThongtang, N., Piyapromdee, J., Tangkittikasem, N., Samaithongcharoen, K., Srikanchanawat, N., & Sriussadaporn, S. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s219496 · Cited by 10
Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome
FITCHETT, D. H., Leiter, L. A., Lin, P., Pickering, J., Welsh, R. C., Stone, J. A., Grégoire, J. C., McFarlane, P. A., Langer, A., Gupta, A. K., et al. (2020) · CJC Open · doi:10.1016/j.cjco.2020.04.002 · Cited by 8
Self-citationFloyd, C. N., & Wierzbicki, A. S. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000759 · Cited by 9
Kommentar zu den Leitlinien (2019) der ESC/EAS zur Diagnostik und Therapie der Dyslipidämien
Weingärtner, O., Landmesser, U., März, W., Katzmann, J. L., Laufs, U., & Kommission für Klinische Kardiovaskuläre Medizin der, D. G. K. (2020) · Der Kardiologe · doi:10.1007/s12181-020-00399-9 · Cited by 10
Aranzulla, T. C., & Musumeci, G. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29231 · Cited by 9
“As shown by large randomized trials there is no risk of achieving and maintaining very low LDL-C values, and no level of LDL-C below which benefit ceases or harm occurs has been identified.(14) Rather, the LDL-C scavenger effect of PCSK9 inhibitors could promote, as in this case, further plaque remodeling and regressi…”
BackgroundIm, J., Kawada‐Watanabe, E., Yamaguchi, J., Arashi, H., Otsuki, H., Matsui, Y., Sekiguchi, H., Fujii, S., Mori, F., Ogawa, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87098-x · Cited by 8
Rached, F. H., & Santos, R. D. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01514-2 · Cited by 9
Optimal medical therapy after coronary artery bypass grafting: a primer for surgeons
Eikelboom, R., Amir, T., Gupta, S. K., & Whitlock, R. P. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000889 · Cited by 9
Special Considerations for Lipid-Lowering Therapy in Women Reflecting Recent Randomized Trials
Agarwala, A., & Goldberg, A. C. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00942-3 · Cited by 8
The challenge of choosing in cardiovascular risk management
Hoogeveen, R. M., Hanssen, N. M. J., Brouwer, J., Mosterd, A., Tack, C. J., Kroon, A. A., de Borst, G. J., ten Berg, J. M., Trier, T. J. V., van Lennep, J. E. R., et al. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01599-y · Cited by 11
Self-citationKunkel, K. J., Lemor, A., Mahmood, S., Villablanca, P., & Ramakrishna, H. (2021) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2021.07.032 · Cited by 8
“67,68 A prespecified analysis from the ODYSSEY trial evaluated the effect of alirocumab-induced changes in lipoprotein A (Lp(a)) and LDL-C on major adverse cardiovascular events.”
Setny, M., Jankowski, P., Kamiński, K. A., Gąsior, Z., Haberka, M., Czarnecka, D., Pająk, A., Kozieł, P., Szóstak-Janiak, K., Sawicka, E., et al. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16179 · Cited by 15
Metzner, T., Leitner, D. R., Dimsity, G., Gunzer, F., Opriessnig, P., Mellitzer, K., Beck, A., Sourij, H., Stojaković, T., Deutschmann, H., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10010152 · Cited by 9
Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin
Nettersheim, F. S., Picard, F. S. R., Hoyer, F. F., & Winkels, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.812702 · Cited by 10
“Two monoclonal antibodies targeting PCSK9, evolocumab (13) and alirocumab (12), and a siRNA-based compound, inclisiran (222, 223), are approved for clinical use in selected high-risk patients.”
BackgroundInfluentialMetzner, T., Leitner, D. R., Mellitzer, K., Beck, A., Sourij, H., Stojaković, T., Reishofer, G., März, W., Landmesser, U., Scharnagl, H., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10010193 · Cited by 10
“The effects of novel proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies on LDL cholesterol and cardiovascular event reduction have thoroughly been investigated [23,24].”
BackgroundConsiderations for routinely testing for high Lp(a)
Nurmohamed, N. S., Moriarty, P. M., & Stroes, E. S. G. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000828 · Cited by 8
“PCSK9 inhibition with evolocumab and alirocumab resulted in a median 27% reduction in Lp(a) levels in the FOURIER and ODYSSEY outcomes trials, respectively [21,22].”
BackgroundKourtidou, C., Rafailidis, V. D., Varouktsi, G., Kanakis, E., Liakopoulos, V., Vyzantiadis, T., Stangou, M. J., Marinaki, S., & Τζιόμαλος, Κ. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071139 · Cited by 8
Yang, W., Cai, X., Lin, C., Lv, F., Zhu, X., Han, X., & Ji, L. (2022) · Medicine · doi:10.1097/md.0000000000030563 · Cited by 9
Lin, P., Wu, Y., Lin, C., Yeh, H., Chang, W., Charng, M., Huang, P., Lin, C., Lin, T., Lin, W.-W., et al. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63789 · Cited by 8
Zhao, X., Song, L., Li, J., Zhou, J., Li, N., Yan, S., Chen, R., Wang, Y., Liu, C., Zhou, P., et al. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s389778 · Cited by 9
Bellino, M., Galasso, G., Silverio, A., Tedeschi, M., Formisano, C., Romei, S., Esposito, L., Cancro, F. P., Vassallo, M. G., Accarino, G., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082922 · Cited by 10
“The efficacy of soluble PCSK9 inhibition for secondary ASCVD prevention is supported by two large cardiovascular outcomes trials—the ODYSSEY OUTCOMES and the FOURIER [41,42].”
BackgroundMethodInfluentialThe role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance
Banerjee, Y., Patti, A. M., Giglio, R. V., Ciaccio, M., Vichithran, S., Faisal, S., Stoian, A. P., Rizvi, A. A., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108517 · Cited by 8
Verghese, D., Muller, L., & Velamakanni, S. V. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01923-5 · Cited by 13
Atherosclerotic Cardiovascular Disease in Women: Providing Protection With Lipid-altering Agents
Hiles, M., Simmons, A., Hilleman, D. E., Gibson, C., & Backes, J. M. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.08.021 · Cited by 11
Liu, Z., Deng, C., Zhao, R., Xu, G., Bai, Z., Wang, Z., Zhang, W., Ma, Y., Hu, X., Jin, C. D., et al. (2023) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-023-02956-1 · Cited by 8
Krychtiuk, K. A., Andersson, T. L., Bodesheim, U., Butler, J., Curtis, L. H., Elkind, M. S. V., Hernandez, A. F., Hornik, C. P. V., Lyman, G. H., Khatri, P., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.01.004 · Cited by 9
Elkind, M. S. V., Arnett, D. K., Benjamin, I. J., Eckel, R. H., Grant, A. O., Houser, S. R., Jacobs, A. K., Jones, D. W., Robertson, R. M., Sacco, R. L., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001213 · Cited by 13
The role of natural products as PCSK9 modulators: A review
Khayatan, D., Zare, K., Khanahmadi, M., Momtaz, S., Butler, A. E., Jamialahmadi, T., Almahmeed, W. A., Abdolghaffari, A. H., & Sahebkar, A. (2024) · Phytotherapy Research · doi:10.1002/ptr.8260 · Cited by 9
“In a randomized clinical trial performed hospitalization due to angina (Schwartz et al., 2018).”
Atherosclerotic Coronary Artery Disease in Patients With Cardiometabolic Syndrome
Miura, S., Shiga, Y., Ike, A., & Iwata, A. (2019) · Cardiology Research · doi:10.14740/cr857 · Cited by 8
“In addition, in patients with a previous acute coronary syndrome who were receiving high-intensity statin therapy (Odyssey Outcomes study), the risk of recurrent ischemic cardiovascular events was lower among patients who received alirocumab (PCSK9 inhibitor) than among those who received placebo [29].”
BackgroundKatsiki, N., & Mikhailidis, D. P. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.04.011 · Cited by 8
Key Articles and Guidelines in the Management of Dyslipidemia: 2019 Update
Wiggins, B. S., Dixon, D. L., Bellone, J. M., Gasbarro, N. M., Marrs, J. C., & Tran, R. J. C. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019868413 · Cited by 8
Welsh, R. C., Peterson, E. D., Caterina, R. D., Bode, C., Gersh, B. J., & Eikelboom, J. W. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.09.006 · Cited by 10
Gencer, B., Carballo, D., Nanchen, D., Koskinas, K. C., Klingenberg, R., Räber, L., Auer, R., Carballo, S., Heg, D., Windecker, S., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.12.011 · Cited by 8
Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES
Goodman, S. G., Steg, P. G., Szarek, M. J., Bhatt, D. L., Bittner, V., Díaz, R., Harrington, R. A., Jukema, J. W., White, H. D., Zeiher, A. M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.030 · Cited by 8
Self-citationPCSK9 Inhibitors: From Nature’s Lessons to Clinical Utility
Raal, F. J., CHILTON, R. J., Ranjith, N., Rambiritch, V., Leisegang, R. F., Ebrahim, I. O., van Tonder, A., Shunmoogam, N., Bouharati, C., Musa, M. G., et al. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200213114138 · Cited by 8
Cordero, A., Rodríguez‐Mañero, M., Bertomeu‐González, V., García‐Acuña, J. M., Baluja, A., Agra-Bermejo, R., Álvarez, B. Á., Cid, B., Zuazola, P., & González‐Juanatey, J. R. (2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2020.03.011 · Cited by 12
Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus
Elharram, M., Sharma, A., White, W. B., Bakris, G. L., Rossignol, P., Mehta, C. R., Ferreira, J. P., & Zannad, F. M. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.07.014 · Cited by 8
Kirchhofer, D., Burdick, D. J., Skelton, N. J., Zhang, Y., & Ultsch, M. H. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190672 · Cited by 9
Schlunk, F., Fischer, P., Princen, H. M. G., Rex, A., Prinz, V., Foddis, M., Lütjohann, D., Laufs, U., & Endres, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112875 · Cited by 10
Faggiano, P. M., Bernardi, N., Calvi, E., Bonelli, A., Faggiano, A., Bursi, F., & Bosisio, M. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.01.004 · Cited by 11
The Management of Coronary Artery Disease in Ethiopia: Emphasis on Revascularization
Shashu, B. A. (2021) · Ethiopian Journal of Health Sciences · doi:10.4314/ejhs.v31i2.27 · Cited by 9
“Serum LDL was reduced by more than 60% over and above high intensity statin treatment in studies that have proven safeties of these drugs , with outcome studies, a composite of cardiovascular death, non-fatal MI, stroke or unstable angina requiring admission was significantly reduced (28,29).”
BackgroundA Less than Provocative Approach for the Primary Prevention of CAD
Roberts, R., & Fair, J. (2021) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-021-10144-6 · Cited by 8
Wittlinger, T., Schwaab, B., Völler, H., Bongarth, C., Heinze, V., Eckrich, K., Guha, M., Richter, M., & Schlitt, A. (2021) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd8090105 · Cited by 10
Weng, S. F., Akyea, R. K., Man, K. K. C., Lau, W. C. Y., Iyen, B., Blais, J. E., Chan, E. W., Siu, C. W., Qureshi, N., Wong, I. C. K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260839 · Cited by 8
“Our study shows that many patients are initiated on low dose statins in the predicted sub-optimal groups suggesting many clinicians may not be aware of the clinical benefits of a stronger treatment regime even in those with lower baseline levels of LDL-C with high risk of CVD. Medications that aim to reduce LDL-C such…”
BackgroundButala, N. M., Jaffer, F. A., & Sabatine, M. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-45792-1_4 · Cited by 10
Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
Kosmas, C. E., Sourlas, A., Silverio, D., Montan, P. D., & Guzman, E. (2019) · World Journal of Cardiology · doi:10.4330/wjc.v11.i11.256 · Cited by 8
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I., Ramdas, S., Zhu, X., Clarke, S., Bhatti, K., Vedantam, S., Winkler, T., et al. (2021) · medRxiv · doi:10.1101/2021.12.15.21267852 · Cited by 11
Rodríguez, F., & Khera, A. (2023) · Circulation · doi:10.1161/circulationaha.123.064041 · Cited by 11
Li, Y., Zhai, Y., Hu, S., Liu, J., Zhang, W., Yue, J., & Wang, Z. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1516326 · Cited by 7
A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease
Rajabian, A., McCloskey, A. P., Jamialahmadi, T., Moallem, S. A., & Sahebkar, A. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0005 · Cited by 7
Medical Management of Coronary Artery Disease in Patients with Chronic Kidney Disease
Kim, J. A., Kim, S. E., Hachem, K. E., Virk, H. U. H., Alam, M., Virani, S. S., Sharma, S. K., House, A. A., & Krittanawong, C. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.06.013 · Cited by 7
The Evaluation and Management of Coronary Artery Disease in the Lung Transplant Patient
Serrao, G. W., Vinayak, M., Nicolas, J., Subramaniam, V., Lai, A. C., Laskey, D. H., Kini, A. S., Seethamraju, H., & Scheinin, S. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247644 · Cited by 8
Zhu, W., Huang, P., Li, R., Ran, J., Dai, W., Tang, Y., Lian, P., Ding, C., & Huang, X. (2024) · The FASEB Journal · doi:10.1096/fj.202301748r · Cited by 8
“9 Therefore, PCSK9 has garnered significant attention in cholesterol metabolism research.”
BackgroundKim, J., Hong, U., Yoon, C. W., Bae, J. W., Rha, J., & Park, H.-K. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1375609 · Cited by 8
“The addition of PCSK9 inhibitors to high-dose statin has been shown to reduce the occurrence of stroke, MI, and cardiovascular death in patients with vascular diseases or high-risk features (5, 6).”
BackgroundMarquis‐Gravel, G., Bhatia, S., Brown, V., & Goodman, S. G. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.05.010 · Cited by 7
Self-citationFrom clinical development to real-world outcomes with inclisiran
Connolly, D. L., Sharma, V., & Ray, K. K. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000954 · Cited by 9
PCSK9 Monoclonal Antibodies Have Come a Long Way
Zendjebil, S., & Steg, P. G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01243-1 · Cited by 8
“…on cardiovascular outcomes was evaluated in the Odyssey Outcomes trial, involving 18,924 patients who had experienced an acute coronary syndrome 1 to 12 months earlier with LDL-C > 70 mg/dL (or non-HDL-C > 100 mg/dL or apolipoprotein B > 80 mg/ dL) despite maximal tolerated statin therapy [24].”
Self-citationPCSK9 Expression in Vascular Smooth Muscle Cells: Role of Insulin Resistance and High Glucose
Barale, C., Tempesta, G., Melchionda, E., Morotti, A., Frascaroli, C., Danzero, A. C., Femminò, S., Penna, C. R. R., & Russo, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031003 · Cited by 10
Parhofer, K. G., Pittrow, D., Birkenfeld, A. L., Fraass, U., Hohenstein, B., Siegert, C., Klotsche, J., Steinhagen‐Thiessen, E., Dexl, S., Schettler, V. J. J., et al. (2025) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2025.2490381 · Cited by 7
Kang, D., Choi, K. H., Yang, S., Kim, H., Park, T. K., Lee, J. M., Cho, J., Yang, J. H., Song, Y. B., Choi, S., et al. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.241713 · Cited by 8
“11,12 Never-theless, none of these trials showed the cost-effectiveness of nonstatin add-on therapy for secondary prevention.”
Владиславович, Е. М., Kukharchuk, V. V., Балахонова, Т. В., Gurevich, V. S., Сергиенко, И. В., Sokolov, A. A., Анатольевич, С. А., Иосифович, Ш. И., Ахмеджанов, Н. М., Барбараш, О. Л., et al. (2025) · Eurasian heart journal · doi:10.38109/2225-1685-2025-2-6-34 · Cited by 11
Maturation of Lipid Management in the 2025 ACC/AHA Acute Coronary Syndrome Guideline
Brandts, J., & Ray, K. K. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.024 · Cited by 7
Review of the potential value of treatment targets in obesity management
Almohaileb, F. I., & le Roux, C. W. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2516522 · Cited by 8
Macrophage-endothelial cell crosstalk drives atherosclerotic plaque formation and progression
Zhang, C., Zhang, Y., Yu, Y., Zhou, M., Zhang, J., Fu, K., & Li, Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177879 · Cited by 11
Intensive Lipid-Lowering Therapy Following Acute Coronary Syndrome: The Earlier the Better
Pradhan, A. K., Sharma, P., Prajapathi, S., Aracri, M., Iellamo, F., & Perrone, M. A. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12080300 · Cited by 11
“…have shown that lowering LDL-C levels beyond maximally tolerated statin therapy is associated with a significant reduction in major adverse cardiovascular events, including a composite of cardiovascular death, myocardial infarction, stroke, coronary revascularization, and unstable angina [30–32].”
InfluentialJabbar, A. B. A., Naeem, U., Zulfiqar, K., Ahmed, S., Inam, M., Hinkamp, C. A., Minhas, A. M. K., Slipczuk, L. N., Krittanawong, C., Sahebkar, A., et al. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01376-x · Cited by 8
“The PCSK9 inhibitor monoclonal antibody evolocumab has shown cardiovascular benefits in patients following MI or stroke [10 , 11].”
Lipid metabolic alterations in cancer: Common pathophysiology with cardiovascular disease
Llena-Meler, M., Canfrán‐Duque, A., Madrigal‐Matute, J., & Rotllán, N. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.01.003 · Cited by 13
Naim, M. A. A. Z., Sumida, K., Streja, E., Thomas, F., Davis, R. L., Kalantar‐Zadeh, K., & Kovesdy, C. P. (2026) · Drugs · doi:10.1007/s40265-025-02275-w · Cited by 8
“Post hoc analyses of the ODYSSEY OUTCOMES [132] and FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) [133] trials documented cardiovascular protection by PCSK9 inhibitors in patients with CKD, alongside lipid-lowering effects.”
Adherence to PCSK9 Inhibitors in Clinical Practice
Blais, J. E., Zhong, W., Li, C. Y. V., Kongkaew, C., & Chan, A. H. Y. (2026) · JACC: Advances · doi:10.1016/j.jacadv.2026.102733 · Cited by 7
Practical guide for the use of PCSK9 inhibitors in Portugal
Fontes‐Carvalho, R., Silva, P. M., Rodrigues, E., Araújo, F., Gavina, C., Ferreira, J., & Morais, J. (2019) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2019.07.004 · Cited by 11
Aortic valve stenosis: drivers of disease progression and drug targets for therapeutic opportunities
Pinto, G., & Fragasso, G. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2118576 · Cited by 9
“ODISSEY trials with high level of evidence and recommendation [111,112].”
BackgroundMarx, N., Wanner, C., Jankowski, J., März, W., Krane, V., & Genser, B. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad029 · Cited by 8
Tandirerung, F. J. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07505-5 · Cited by 7
“…previous history of acute coronary syndrome (ACS) treated with high-intensity statins demonstrated a significant reduction in the recurrence of ischemic cardiovascular events compared to placebo (9.5% occurrence in alirocumab vs. 11.1% in the placebo group; hazard ratio 0.85; p value < 0.001) [27].”
InfluentialSchiele, F., Catapano, A. L., Caterina, R. D., Laufs, U., Jukema, J. W., Zaman, A., & Sionís, A. (2023) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad119 · Cited by 15
“The clinical impact of the earlier use of PCSK9i was not only demonstrated in the ODYSSEY-OUTCOMES study 44 but also in the FOURIER study (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), where the clinical benefit of the additional PSCK9i was more…”
MethodSelf-citationNucleic Acid Delivery Nanotechnologies for In Vivo Cell Programming
Balcorta, H. V., Guerrero, V., Bisht, D., & Poon, W. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00886 · Cited by 9
Impact of Lipid-lowering Therapy on Cancer Risk: A Narrative Review
Pasha, R., Bashir, B., Omed, D., Adam, S., Kamath, A., Elhofy, A., Ferdousi, M., Azmi, S., & Soran, H. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.03.004 · Cited by 8
Zhang, A. M. C., Ziogos, E., Harb, T., Gerstenblith, G., & Leucker, T. M. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14272 · Cited by 7
“…of ASCVD, 8 therapeutic strategies targeting PCSK9 swiftly transitioned from experimental research to clinical application, culminating in the U.S. Food and Drug Administration (FDA) approval of two monoclonal antibodies, alirocumab 2,9 and evolocumab, 1,10 and the siRNA inclisiran 11 (Table 1).”
Xiao, G., Gao, S., Xie, Y., Wang, Z., & Shu, M. (2024) · Medicina · doi:10.3390/medicina60101646 · Cited by 9
“Two fully human monoclonal antibodies (mAbs) for inhibiting PCSK9, evolocumab and alirocumab, have been shown to reduce cardiovascular events in adult patients with ASCVD, and also LDL-C and other lipid parameters among pediatric patients with HeFH in randomized controlled trials (RCTs) [15–18].”
BackgroundStatin alternatives for the treatment of hypercholesterolemia - a safety evaluation
Zeng, W., & Tomlinson, B. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2424411 · Cited by 8
“[42].”
InfluentialRecomendaciones preventivas vasculares. Actualización PAPPS 2024
Orozco‐Beltrán, D., Brotons-Cuixart, C., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Martín-Rioboó, E., Jordá-Baldó, A., Vicuña, J., & Navarro-Pérez, J. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103123 · Cited by 13
Triglycerides and the Risk of Atherosclerotic Cardiovascular Events Across Different Risk Categories
Mizuta, H., Ishii, M., Ikebe, S., Otsuka, Y., Yamanouchi, Y., Nakamura, T., & Tsujita, K. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65334 · Cited by 9
He, W., Zhao, H., Xue, W., Luo, Y. M., Yan, M., Li, J., Qing, L., Wu, W., & Jin, Z. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s487476 · Cited by 11
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

